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Angiotensin-converting enzyme 2 (ACE2) degrades
angiotensin II to angiotensin-(1–7) and is expressed in
podocytes. Here we overexpressed ACE2 in podocytes in
experimental diabetic nephropathy using transgenic
methods where a nephrin promoter drove the expression of
human ACE2. Glomeruli from these mice had significantly
increased mRNA, protein, and activity of ACE2 compared to
wild-type mice. Male mice were treated with streptozotocin
to induce diabetes. After 16 weeks, there was no significant
difference in plasma glucose levels between wild-type and
transgenic diabetic mice. Urinary albumin was significantly
increased in wild-type diabetic mice at 4 weeks, whereas
albuminuria in transgenic diabetic mice did not differ
from wild-type nondiabetic mice. However, this effect
was transient and by 16 weeks both transgenic and
nontransgenic diabetic mice had similar rates of proteinuria.
Compared to wild-type diabetic mice, transgenic diabetic
mice had an attenuated increase in mesangial area,
decreased glomerular area, and a blunted decrease in
nephrin expression. Podocyte numbers decreased in wild-
type diabetic mice at 16 weeks, but were unaffected in
transgenic diabetic mice. At 8 weeks, kidney cortical
expression of transforming growth factor-b1 was significantly
inhibited in transgenic diabetic mice as compared to
wild-type diabetic mice. Thus, the podocyte-specific
overexpression of human ACE2 transiently attenuates the
development of diabetic nephropathy.
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Angiotensin-converting enzyme 2 (ACE2), a recently dis-
covered member of the renin–angiotensin system, has a single
catalytic domain and shares 40% homology with ACE.1,2
Despite this similarity, ACE2 activity is not affected by ACE
inhibitors, nor does it generate angiotensin (Ang) II. On the
contrary, ACE2 degrades Ang II to Ang-(1–7), a peptide that
antagonizes Ang II signaling.3–5 ACE2 also degrades Ang I to
Ang-(1–9) that is subsequently converted to Ang-(1–7) by
ACE.6 Because of these properties, ACE2 has been postulated
to be an endogenous renoprotective enzyme.7
ACE2 may be involved in the pathogenesis of diabetic
nephropathy. Pharmacological inhibition of ACE2 in strep-
tozotocin (STZ)-induced diabetic mice causes increased
albuminuria and expansion of the glomerular matrix.8 In
Akita mice, a model of type 1 diabetes, deletion of the ACE2
gene has been reported to exacerbate albuminuria, associated
with increased mesangial matrix deposition, glomerular
basement membrane thickening, and glomerulosclerosis,
without significant changes in blood pressure (BP).9 Recently,
administration of human recombinant ACE2 to diabetic
Akita mice significantly reduced albuminuria, associated with
decreased BP.10 Similarly, intravenous administration of
recombinant adenovirus carrying the mouse ACE2 gene to
rats with STZ-diabetes was associated with diminished
albuminuria and glomerulosclerosis, although systolic BP
was also reduced.11 Accordingly, there is increasing interest in
the potential therapeutic action of ACE2 amplification to
treat diabetic nephropathy, as recently reviewed.12
Glomerular podocytes are terminally differentiated epithe-
lial cells that are key components of the selective permeability
barrier of the glomerular basement membrane.13 Podocyte
apoptosis and detachment are directly correlated with the
progression of diabetic nephropathy.14 ACE2 has been
localized to the podocyte, and podocyte ACE2 expression
decreases in experimental diabetes.15 However, there is no
direct evidence regarding ACE2 overexpression in the
podocyte as a protector against the development of diabetic
nephropathy. In the current study, transgenic (TG) mice were
generated that selectively overexpress human ACE2 in the
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podocyte to address this question. Specifically, we wished
to examine the hypothesis that a podocyte-specific ACE2
transgene could protect against glomerular injury in the STZ
model of diabetes, independent of changes in BP.
RESULTS
TG mouse characterization
TG mice with podocyte-specific overexpression of human
ACE2 were characterized by reverse transcriptase–PCR,
immunoblot analysis of isolated glomeruli, direct immuno-
fluorescence, and measurement of glomerular ACE2 activity.
By real-time reverse transcriptase–PCR, human ACE2 mRNA
was readily detected in glomeruli from TG mice, at a level
B50-fold higher than in kidney cortex (Figure 1a). In
contrast, the levels of endogenous mouse ACE2 mRNA in TG
mice were significantly lower in glomeruli than in kidney
cortex (Figure 1b). In wild-type (WT) mice, levels of
endogenous mouse ACE2 mRNA were also significantly
lower in glomeruli than kidney cortex (n¼ 4, not shown). In
TG mice, expression of endogenous mouse ACE2 in kidney
cortex was not significantly affected by the presence of the
human ACE2 transgene (relative levels of mouse ACE2
mRNA, TG vs. WT mice: 1.8±1.1-fold, P¼not significant,
n¼ 3). Similarly, glomerular expression of endogenous
mouse ACE2 was not affected by the human ACE2 transgene
(WT: 1.37±0.19 vs. TG: 1.65±0.33 arbitrary units, P¼not
significant, n¼ 2–4). Expression of the human ACE2
transgene was also not detected at significant levels in the
heart, brain, liver, spleen, or lung (Figure 1a).
In glomerular isolates from TG mice, the human ACE2
protein was detected by immunoblot as a single protein band
ofB120 kDa, compared with the endogenous mouse ACE2 at
B100 kDa (Figure 1c). In TG mice, the human ACE2 protein
was not readily detected in kidney cortical homogenates
(Figure 1c). By immunofluorescence of kidney cortical tissue,
TG mice demonstrated positive glomerular staining for the
hemagglutinin epitope tag, which colocalized with the
podocyte protein synaptopodin (Figure 1d). In freshly
isolated glomeruli, ACE2 enzymatic activity was significantly
increased in TG mice as compared with WT mice (Figure 1e:
2.82-fold increase in TG vs. WT mice, Po0.02, n¼ 9–10).
STZ-diabetes: whole animal data
Table 1 depicts whole animal data regarding body and organ
weights, and plasma glucose. WT and TG mice treated with
STZ (WT-STZ and TG-STZ, respectively) developed severe
diabetes, with significantly increased plasma glucose compared
with vehicle-treated mice, and with no significant difference
between the two STZ groups. TG mice had lower body weights
than WT mice matched for age. However, both WT-STZ and
TG-STZ mice experienced weight loss, and renal hypertrophy,
inferred from increased kidney weight to body weight ratio
(Po0.001 vs. non-STZ mice). In contrast, there was no
difference in cardiac weight to body weight ratios among the
four groups. Despite the high levels of plasma glucose, diabetic
mice did not develop ketosis, as determined by urine testing at
16 weeks, and absence of metabolic acidosis (not shown).
Mortality rate was 12.2% (11/90) for all mice in the study, with
no significant differences among the four groups. In TG-STZ
mice, glomerular ACE2 activity remained significantly in-
creased after 16 weeks as compared with WT-STZ
(3.30±0.88-fold increase, Po0.01, n¼ 5). By immunofluor-
escent staining, glomerular ACE2 expression was significantly
increased in TG mice when compared with WT mice
(Po0.001), and this increase persisted 16 weeks after STZ
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Figure 1 |Characterization of transgenic (TG) mice.
(a) Expression of mRNA for the human angiotensin-converting
enzyme 2 (ACE2) transgene in tissues from TG mice. Graph shows
relative levels of human ACE2 mRNA in various mouse tissues,
determined by real-time reverse transcriptase–PCR (RT–PCR).
*Po0.001, glomeruli vs. all other tissues; n¼ 3 (glomeruli) and
n¼ 6–7 for other tissues. (b) Expression of endogenous mouse
ACE2 mRNA in glomeruli and kidney cortex from TG mice. Graph
depicts relative expression of mouse ACE2 mRNA in glomeruli and
kidney cortex from TG mice, determined by real-time RT–PCR.
*Po0.02; n¼ 3. (c) Immunoblot analysis of ACE2 in glomeruli and
cortex tissue. Shown is representative immunoblot of ACE2
protein in glomeruli and kidney cortex from wild-type (WT) and
TG mice, with or without treatment with STZ, at 16 weeks (n¼ 2).
Human ACE2 transgenic protein is present as a single band at
B120 kDa in glomeruli from TG or TG-STZ mice. Endogenous
mouse ACE2 protein is observed in all lanes as a single band at
B100 kDa. (d) Colocalization of human ACE2 transgene with
podocyte protein synaptopodin. Dual-color immunofluorescence
was performed on kidney sections from TG mice. Sections were
stained with rabbit polyclonal antibody to hemagglutinin (HA;
present in the transgene as a double epitope tag; left panel), and
with rabbit polyclonal anti-synaptopodin antibody (middle panel).
Merged view is shown in the panel on the right. Original
magnification  400. (e) Glomerular ACE2 activity. ACE2 activity
was measured in isolated glomeruli from WT or TG mice, as
described in Materials and Methods. *Po0.02, n¼ 9 (WT),
n¼ 10 (TG).
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injection (Figure 2). Glomerular human ACE2 protein
expression by immunoblot also remained robust at 16 weeks
(Figure 1c). At this time point, in contrast, plasma ACE2
activity was actually decreased in TG-STZ mice compared with
WT-STZ mice (TG-STZ: 0.25±0.03 vs. WT-STZ: 0.32±
0.04 ng-eq/ml plasma, Po0.05, n¼ 6; Figure 3). However, both
diabetic groups had higher plasma ACE2 activity compared
with non-STZ groups (Po0.001).
At 16 weeks, there were no significant differences in
plasma electrolytes, total protein, or total cholesterol between
WT-STZ and TG-STZ mice (not shown). WT-STZ mice had
significant elevations in serum triglycerides compared with
all other groups (Po0.01).
Systolic BP
Systolic BP was measured weekly throughout the study and
tended to be higher in both groups of STZ mice when
compared with non-STZ mice, but the difference was not
significant until the 15-week time point (Figure 4). Systolic
BP did not significantly differ between WT-STZ and TG-STZ
mice at any point in the study, nor did it differ between WT
and TG mice (Figure 4).
Glomerular filtration rate
At 16 weeks, glomerular filtration rate was significantly
higher in WT-STZ and TG-STZ mice when compared with
WT and TG mice, but there was no difference between the
two STZ groups (Figure 5).
Albuminuria
At 4 weeks, WT-STZ mice had significantly increased levels
of albuminuria as compared with vehicle-treated mice
(Figure 6a). In contrast, TG-STZ mice had no increase in
albuminuria at 4 weeks (Po0.05 vs. WT-STZ, n¼ 5).
However, there was no significant difference in albuminuria
between WT-STZ and TG-STZ mice at 8 weeks (WT-STZ:
1312±527 vs. TG-STZ: 1233±380mg per 24 h; P¼ not
significant, n¼ 6). Similarly, at 16 weeks, both WT-STZ and
TG-STZ mice had markedly increased levels of albumin-
uria, with no significant difference between the two groups
Table 1 |Whole animal data
WT TG WT-STZ TG-STZ
BW (g) 36.2±0.7 (6) 31.1±1.1 (7)** 27.2±0.5 (8)* 25.9±0.5 (6)*
KW/BW (g/kg) 11.4±0.4 (6) 12.2±0.2 (7) 20.8±0.7 (8)*** 21.0±1.3 (6)***
HW/BW (g/kg) 3.9±0.3 (6) 4.3±0.1 (7) 4.3±0.2 (8) 4.2±0.2 (6)
Plasma
glucose
(mmol/l)
19.1±1.0 (11) 18.3±1.3 (11) 55.8±8.0 (11)w 72.2±17.1 (11)w
Abbreviations: BW, body weight; HW, heart weight; KW, kidney weight; TG,
transgenic; TG-STZ, transgenic streptozotocin-treated; WT, wild type; WT-STZ, wild-
type streptozotocin-treated.
Values are means±s.e. (n).
*Po0.001 vs. WT and *Po0.01 vs. TG.
**Po0.01 vs. WT.
***Po0.001 vs. WT and TG.
wPo0.05 vs. WT and TG.
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Figure 2 |Glomerular expression of angiotensin-converting
enzyme 2 (ACE2) by immunofluorescence at 16 weeks. Graph
depicting semiquantitative analysis of ACE2 immunofluorescent
staining in mouse glomeruli at 16 weeks. TG, podocyte-specific
ACE2 transgenic; TG-STZ, transgenic streptozotocin-treated; WT,
wild type; WT-STZ, wild-type streptozotocin-treated. Values are
means±s.e. *Po0.001 vs. WT and vs. WT-STZ; n¼ 100 glomeruli
per group, from 6 to 11 mice per group. Representative images
depicting ACE2 staining in glomeruli (red) at 16 weeks are shown
above graph. Blue staining represents Hoechst nuclear stain.
Original magnification  640.
WT TG WT-STZ TG-STZ
0.0
0.1
0.2
0.3
0.4
* $
AC
E2
 a
ct
ivi
ty
(ng
 eq
/μl
 p
la
sm
a) #
Figure 3 |Plasma angiotensin-converting enzyme 2 (ACE2)
activity. Graph depicts plasma ACE2 enzymatic activity from
wild-type (WT), transgenic (TG), wild-type streptozotocin-treated
(WT-STZ), and transgenic streptozotocin-treated (TG-STZ) mice
at 16 weeks. Values are means±s.e. *Po0.001 vs. WT and TG,
#Po0.001 vs. WT and TG, $Po0.05 vs. TG-STZ; n¼ 6.
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(Figure 6b). Coomassie blue staining of sodium dodecyl
sulfate gels revealed generalized proteinuria in STZ-treated
mice compared with nondiabetic mice (Figure 6c).
Histological analysis and expression of podocyte proteins
Histological analysis was performed on kidney sections at 8
and 16 weeks. At 8 weeks, WT-STZ mice and TG-STZ mice
demonstrated increases in mesangial and glomerular areas
compared with vehicle-treated mice (Figure 7). The increase
in mesangial area, however, was significantly attenuated in
TG-STZ mice. At 16 weeks, mesangial and glomerular areas
were significantly increased in WT-STZ and TG-STZ groups
as compared with nondiabetic mice (Figure 8). Glomerular
diameter was significantly diminished in TG-STZ mice when
compared with WT-STZ mice (Figure 8).
Expression of the podocyte protein nephrin was examined
by immunoblots and immunofluorescence. In kidney cortical
lysates from WT-STZ mice, nephrin expression by immuno-
blot was significantly decreased at 8 weeks as compared with
WT mice (Figure 9a). TG-STZ mice, in contrast, exhibited no
significant difference in nephrin expression compared with
their TG counterparts, although baseline levels were lower.
Similarly, at 16 weeks, nephrin expression was significantly
reduced in WT-STZ mice compared with WT mice, whereas
nephrin levels did not significantly differ between TG and
TG-STZ mice (Figure 9b). Semiquantitative immunofluor-
escence analysis at 8 and 16 weeks revealed a similar pattern
of glomerular nephrin expression as the immunoblots
(Figure 10). In particular, whereas nephrin expression was
significantly reduced in WT-STZ mice, there was no
significant difference in nephrin expression between TG
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Figure 4 | Systolic blood pressure (BP). Systolic BP was
measured weekly by tail-cuff plethysmography. TG, transgenic;
TG-STZ, transgenic streptozotocin-treated; WT, wild type; WT-STZ,
wild-type streptozotocin-treated. Values are means±s.e. *Po0.01
vs. WT and TG, **Po0.05 vs. WT and TG. There was no significant
difference between WT-STZ and TG-STZ mice; n¼ 14 mice per
group.
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Figure 5 |Glomerular filtration rate (GFR). Graph shows GFR
measurements in wild-type (WT), transgenic (TG), wild-type
streptozotocin-treated (WT-STZ), and transgenic streptozotocin-
treated (TG-STZ) mice after 16 weeks. Values are means±s.e.
*Po0.05 vs. WT and TG, #Po0.01 vs. WT and TG; n¼ 4–6.
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Figure 6 |Urinary protein excretion. (a) The 24 h urinary
albumin excretion in wild-type (WT), transgenic (TG), wild-type
streptozotocin-treated (WT-STZ), and transgenic streptozotocin-
treated (TG-STZ) mice at 4 weeks. *Po0.05 vs. all other groups
(WT, TG, and TG-STZ mice); n¼ 5. (b) The 24 h urinary albumin
excretion at 16 weeks. *Po0.01 vs. WT and TG, #Po0.01 vs. WT
and TG. There was no significant difference between WT-STZ and
TG-STZ mice; n¼ 14. (c) Representative Coomassie blue-stained
sodium dodecyl sulfate (SDS) gel of urine samples from WT, TG,
WT-STZ, and TG-STZ mice at 8 weeks. Multiple protein bands
are evident in urine samples from WT-STZ and TG-STZ mice.
Molecular weight marker is depicted in the first and last lanes.
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Figure 7 | Effect of podocyte angiotensin-converting enzyme 2 (ACE2) overexpression on mesangial and glomerular area at
8 weeks. Graphs depict (a) mesangial and (b) glomerular areas at 8 weeks in wild-type (WT), transgenic (TG), wild-type streptozotocin-treated
(WT-STZ), and transgenic streptozotocin-treated (TG-STZ) mice. (a) Mesangial area at 8 weeks. Values are means±s.e. (n¼ 40 glomeruli per
group of 4 mice). *Po0.001 vs. WT and TG, #Po0.02 vs. WT and TG, $Po0.03 vs. TG-STZ. (b) Glomerular area at 8 weeks. Values are
means±s.e. (n¼ 40 glomeruli per group of 4 mice). *Po0.001 vs. WT and TG, #Po0.001 vs. WT and TG. There was no significant difference
between WT-STZ and TG-STZ mice. (c) Representative photomicrographs depicting periodic acid–Schiff (PAS)-stained glomeruli in WT, TG,
WT-STZ, and TG-STZ mice at 8 weeks. Glomerular hypertrophy and increased mesangial staining are evident in STZ groups as compared
with non-STZ mice. Original magnification  640.
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Figure 8 | Effect of podocyte angiotensin-converting enzyme 2 (ACE2) overexpression on mesangial and glomerular area at
16 weeks. Graphs depict (a) mesangial and (b) glomerular areas at 16 weeks in wild-type (WT), transgenic (TG), wild-type streptozotocin-
treated (WT-STZ), and transgenic streptozotocin-treated (TG-STZ) mice. (a) Mesangial area at 16 weeks. Values are means±s.e. (n¼ 60
glomeruli per group of 6 mice). *Po0.001 vs. WT and TG, #Po0.001 vs. WT and TG. There was no significant difference between WT-STZ and
TG-STZ mice. (b) Glomerular area at 16 weeks. Values are means±s.e. (n¼ 60 glomeruli per group of 6 mice). *Po0.001 vs. WT and TG,
#Po0.001 vs. WT and TG, $Po0.001 vs. TG-STZ. (c) Representative photomicrographs depicting periodic acid–Schiff (PAS)-stained glomeruli
in WT, TG, WT-STZ, and TG-STZ mice at 16 weeks. Glomerular hypertrophy and increased mesangial staining is evident in STZ groups as
compared with non-STZ mice. Original magnification  640.
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and TG-STZ mice, although TG mice tended to have lower
expression than WT mice.
By immunofluorescence, glomerular synaptopodin ex-
pression was not significantly affected at 8 weeks, although
there was a tendency for reduced expression in WT-STZ and
TG-STZ mice (Figure 11). However, at 16 weeks, expression
of synaptopodin was significantly reduced in WT-STZ
mice when compared with WT, TG, or TG-STZ mice
(Figure 11).
Podocyte numbers were assayed at 8 and 16 weeks by
counting glomerular nuclei staining positively for WT-1. At
8 weeks, both WT-STZ and TG-STZ mice had significantly
decreased podocyte number per glomerulus compared
with non-STZ mice (Figure 12a). In TG mice, podocyte
number was lower than in WT mice, and the decrease with
STZ was less pronounced compared with WT-STZ mice. At
16 weeks, WT-STZ mice showed a significant decrease in
average podocyte number compared with vehicle-treated
mice. In contrast, TG-STZ mice did not exhibit a significant
decrease in podocytes as compared with nondiabetic mice
(Figure 12b).
Kidney cortical expression of TGF-b1
As shown in Figure 13, protein expression of the profibrotic
cytokine transforming growth factor-b1 (TGF-b1) was
significantly increased in kidney cortices from WT-STZ
mice at 8 weeks when compared with nondiabetic mice.
In contrast, TG-STZ mice exhibited no increase in cortical
TGF-b1 at 8 weeks. At 16 weeks, expression of TGF-b1 was
increased in both WT-STZ and TG-STZ mice, with no
significant difference between the two groups.
DISCUSSION
The major finding of this study is that overexpression of
human ACE2 in the glomerular podocyte attenuates the
development of nephropathy in mouse STZ-diabetes. This
was shown by (1) a delay in the development of albuminuria,
independent of any effect on systolic BP; (2) histological
evidence of renal protection, namely an early reduction in
mesangial expansion, and attenuation of glomerular hyper-
trophy at 16 weeks; (3) partial preservation of expression of
the podocyte proteins nephrin and synaptopodin; (4)
prevention of podocyte loss by ACE2 overexpression; and
(5) reduction in cortical TGF-b1 expression at 8 weeks. In
addition to protection against diabetic nephropathy, this
model of ACE2 overexpression should be useful to examine
questions related to pathology and progression of CKD in
other forms of glomerular injury.
Podocytes are highly specialized cells that form a critical
component of the glomerular filtration barrier to proteins.
Cultured podocytes express components of the renin–angio-
tensin system,16–18 and ACE2 has been localized to the
podocyte in glomeruli from diabetic mice by immunohis-
tochemistry and immunogold staining.15 Loss of podocytes
via apoptosis contributes importantly to the pathogenesis of
diabetic nephropathy. Multiple signaling pathways may
mediate podocyte apoptosis in diabetes, including involve-
ment of mammalian target of rapamycin signaling.19
However, Ang II is recognized as a key contributor to
podocyte apoptosis, via interaction with AT1 (angiotensin II
receptor, type 1) receptors, and production of reactive oxygen
species.20,21 In cultured podocytes exposed to high glucose,
production of Ang II is enhanced, which may contribute to
AT1 receptor–mediated apoptosis.
16 In the db/db mouse
model of type 2 diabetes, podocyte ACE2 expression is
decreased,15 and renal biopsy specimens from humans with
diabetic nephropathy similarly demonstrate decreased glo-
merular ACE2 mRNA and protein expression.22 As ACE2
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Figure 9 |Nephrin expression at 8 and 16 weeks by
immunoblot. (a) Graph depicting nephrin expression by
immunoblot analysis of cortical lysates in wild-type (WT),
transgenic (TG), wild-type streptozotocin-treated (WT-STZ), and
transgenic streptozotocin-treated (TG-STZ) mice at 8 weeks.
Representative immunoblot is shown above graph, with nephrin
at B185 kDa, and b-actin signal below, as control for protein
loading. Values are mean±s.e., n¼ 6 per group. *Po0.02 vs. WT.
There was no significant difference between TG and TG-STZ mice
or between WT-STZ and TG-STZ mice. (b) Graph depicting nephrin
expression by immunoblot analysis of cortical lysates in WT,
TG, WT-STZ, and TG-STZ mice at 16 weeks. Representative
immunoblot is shown above graph, with nephrin at B185 kDa,
and b-actin signal below, as control for protein loading. Values are
mean±s.e., n¼ 6 per group. *Po0.05 vs. WT. There was no
significant difference between TG and TG-STZ mice.
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degrades Ang II to Ang-(1–7), strategies to preserve or
enhance podocyte ACE2 could prevent local increases in Ang
II levels. Furthermore, ACE2 leads to enhanced production of
Ang-(1–7), which has been associated with improvement of
albuminuria in experimental diabetes.23
The glomerular ACE2-specific TG mice that we describe in
this study did not exhibit major phenotypic differences
compared with WT counterparts. For unclear reasons, TG
mice had lower body weights compared with WT mice
matched for age. However, both WT-STZ and TG-STZ mice
developed similar elevations of plasma glucose, associated
with loss of body weight, kidney hypertrophy, glomerular
hyperfiltration, and parallel increases in systolic BP. The
human ACE2 cDNA was linked to the mouse nephrin
promoter in these studies, as nephrin gene expression is
relatively specific to podocytes.24 Several lines of evidence
support the conclusion that human ACE2 was selectively
overexpressed in podocytes from TG mice. First, robust
mRNA expression of the transgene occurred in glomeruli
from TG mice, at a levelB50-fold higher than that in kidney
cortex, whereas endogenous mouse ACE2 expression was
lower in glomeruli than cortex. Other tissues from TG mice,
including brain (which expresses nephrin24) did not
significantly express human ACE2 mRNA. Second, by
immunoblot, the human ACE2 protein was detected in
glomerular isolates, but not kidney cortex, as a protein of
B120 kDa. Third, the ACE2 protein colocalized with
synaptopodin by immunofluorescence, indicating its pre-
sence in the podocyte. Fourth, ACE2 activity was significantly
enhanced in glomeruli from TG mice, and elevated activity
(and glomerular expression by immunoblot and immuno-
fluorescence) persisted after 16 weeks of STZ-diabetes. In this
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Figure 10 |Nephrin expression at 8 and 16 weeks by immunofluorescence. (a) Graph depicting semiquantitative analysis of nephrin
expression by immunofluorescence in wild-type (WT), transgenic (TG), wild-type streptozotocin-treated (WT-STZ), and transgenic
streptozotocin-treated (TG-STZ) mice at 8 weeks. Values are means±s.e., n¼ 100 glomeruli per group, from 7 to 8 mice per group.
*Po0.001 vs. WT. There was no significant difference between TG and TG-STZ mice. Representative images depicting glomerular nephrin
expression (red) at 8 weeks are shown above graph. Nuclear Hoechst staining (blue) is also shown. Original magnification  640. (b) Graph
depicting nephrin expression by immunofluorescence at 16 weeks. Values are means±s.e., n¼ 100 glomeruli per group, from 6 to 11 mice
per group. *Po0.001 vs. WT. Representative images depicting glomerular nephrin expression (red) at 16 weeks are shown above graph.
Nuclear Hoechst staining (blue) is also shown. Original magnification  640.
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regard, nephrin expression decreases in diabetic nephrop-
athy,25,26 and nephrin deficiency is associated with activa-
tion of nuclear factor-kB–mediated pathways that enhance
glomerular injury.27 Our data suggest that the nephrin
promoter remained active and stimulated transcription of the
human ACE2 gene in TG-STZ mice, despite the presence of
severe diabetes. Finally, selective overexpression of the human
ACE2 gene in podocytes was not associated with changes in
systolic BP. Plasma ACE2 activity did not increase above the
level of WT-STZ mice, in keeping with the localized increase
in ACE2 at the podocyte level.
In WT-STZ mice, a significant increase in albuminuria
occurred at 4 weeks as compared with nondiabetic mice.
In contrast, urinary albumin excretion in TG-STZ mice at
4 weeks did not differ from levels in non-diabetic mice.
The 24 h albuminuria levels in our diabetic mouse model were
significantly higher than those reported by Qi et al.28 in FVB
mice with STZ-diabetes. There is considerable variability in
urinary albumin measures in mouse models of diabetes, and
assay procedures differ. Studies using the same assay
procedure we used in this study have reported high measures
of urinary albumin in other mouse strains with diabetes.29,30
Despite the initial prevention of albuminuria in TG-STZ
mice, albuminuria increased to the level of WT-STZ mice at
later time points. In diabetes, increased Ang II is thought to
promote podocyte dysfunction and albuminuria. Ang II
reduces expression of the antioxidant protein peroxiredoxin 2
in podocytes in vitro and in vivo, associated with increased
production of reactive oxygen species, inhibition of the Akt
pathway, and apoptosis.20 As TG-STZ mice were only
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Figure 11 | Synaptopodin expression at 8 and 16 weeks by immunofluorescence. (a) Graph depicting semiquantitative analysis of
synaptopodin expression by immunofluorescence in wild-type (WT), transgenic (TG), wild-type streptozotocin-treated (WT-STZ), and
transgenic streptozotocin-treated (TG-STZ) mice at 8 weeks. Values are means±s.e., n¼ 100 glomeruli per group, from 7 to 8 mice per
group. There was no significant difference among the groups. Representative images depicting glomerular synaptopodin expression
(green) at 8 weeks are shown above graph. Nuclear Hoechst staining (blue) is also shown. Original magnification  640. (b) Graph depicting
synaptopodin expression at 16 weeks. Values are means±s.e., n¼ 100 glomeruli per group, from 6 to 11 mice per group. *Po0.001 vs. WT
and TG, **Po0.001 vs. WT-STZ. There was no significant difference between TG and TG-STZ mice. Representative images depicting
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protected against albuminuria at 4 weeks, podocyte ACE2
activity may not have been sufficiently enhanced at later time
points to reduce this Ang II–mediated adverse signaling, or
other non-Ang II–dependent pathways affecting podocyte
function may have dominated and contributed to albumin-
uria.
Nonetheless, the early reduction in albuminuria in TG-
STZ mice was associated with improvement in features of
diabetic nephropathy. First, a significant decrease in mesan-
gial area occurred at 8 weeks, with decreased glomerular
hypertrophy at 16 weeks. Second, expression of the podocyte
proteins nephrin and synaptopodin, reported to be decreased
in diabetic models,31,32 was partly preserved in TG-STZ mice.
In TG mice, baseline nephrin expression was decreased
compared with WT mice, and treatment with STZ did not
induce a further decrease. As our model used the mouse
nephrin promoter to induce podocyte-specific ACE2 over-
expression, the decrease in basal nephrin expression in TG
mice could be because of competition for transcription
factors between the nephrin gene and the transgene.
Importantly, partial protection against loss of podocyte
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Figure 12 |Podocyte number at 8 and 16 weeks. (a) Graph
shows average number of podocytes per glomerulus in wild-type
(WT), transgenic (TG), wild-type streptozotocin-treated (WT-STZ),
and transgenic streptozotocin-treated (TG-STZ) mice at 8 weeks,
as determined by counting of WT-1-positive nuclei in kidney
sections. Values are means±s.e., n¼ 78–106 glomeruli per 7 to 8
mice in each group. *Po0.001 vs. WT and TG, #Po0.01 vs. TG,
$Po0.01 vs. WT. (b) Podocyte numbers at 16 weeks. Values are
means±s.e., n¼ 120 glomeruli per 6 mice in each group. *Po0.01
vs. WT and TG. There was no significant difference between
TG-STZ and WT, TG, or WT-STZ mice. (c) Representative
photomicrograph depicting glomerular WT-1 staining in
glomeruli from WT-STZ vs. TG-STZ mice at 16 weeks. Original
magnification  400.
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Figure 13 | Expression of transforming growth factor-b1
(TGF-b1) at 8 and 16 weeks. (a) Graph shows expression of TGF-
b1 in kidney cortical lysates from wild-type (WT), transgenic
(TG), wild-type streptozotocin-treated (WT-STZ), and transgenic
streptozotocin-treated (TG-STZ) mice at 8 weeks, by immunoblot.
Values are means±s.e., n¼ 6 per group. *Po0.02 vs. all other
groups (WT, TG, and TG-STZ). Above graph is a representative
immunoblot for TGF-b1, depicting bands at 12.5 and 25 kDa, the
latter representing the TGF-b1 dimer. Blot for b-actin, as loading
control, is depicted below. (b) Graph shows expression of TGF-b1
from cortical lysates at 16 weeks, with representative immunoblot
above graph. Values are means±s.e., n¼ 6 per group. *Po0.05
vs. WT and TG. **Po0.01 vs. WT and TG. There was no significant
difference between WT-STZ and TG-STZ mice.
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number was evident at 16 weeks, but not at 8 weeks. Finally,
the expression of TGF-b1 in kidney cortex was significantly
attenuated in TG-STZ mice at 8 weeks. We postulate that this
partial protection is because of enhanced ACE2-dependent
degradation of Ang II in the diabetic glomerulus. Our data
support the hypothesis that in the diabetic kidney, glomerular
Ang II initiates a reduction in nephrin and synaptopodin
expression, and stimulation of TGF-b1, which induces
podocyte loss (diabetic podocytopathy), leading to proteinuria
and subsequent tubulointerstitial inflammation and fibrosis,
which in turn is associated with increased elaboration of TGF-
b1.33 Consistent with this view, in rats with STZ-diabetes,
intravenous adenoviral gene transfer of ACE2 reduces kidney
cortical levels of Ang II, and increases Ang-(1–7), associated
with protection from glomerular injury.11 In rat mesangial
cells, transfection of ACE2 inhibits Ang II–stimulated cell
proliferation, oxidative stress, and collagen IV synthesis.11
Although the beneficial effects of ACE2 may have derived
largely from a reduction in Ang II levels in our study, the role
of potentially enhanced podocyte generation of Ang-(1–7) in
TG mice remains unclear. Although Ang-(1–7) inhibits Ang
II–mediated proinflammatory signaling in proximal tubular
cells and the vasculature,3–5 its effects on podocyte function
are unknown. In mesangial cells, Ang-(1–7) has been reported
to either stimulate profibrotic pathways34 or inhibit Ang II
signaling.35 Thus, although overexpression of ACE2 in the
podocyte has a renoprotective effect, the relative contribution
of diminished levels of Ang II versus increased Ang-(1–7)
requires further study. Finally, this study focused on early
diabetic nephropathy, and the long-term effects of over-
expression of ACE2 on disease progression remain unclear.
In summary, after STZ-induced diabetes, TG mice with
podocyte-specific overexpression of the human ACE2 protein
are protected against the early development of albuminuria
and show partial preservation of podocyte proteins and
podocyte number, reduced glomerular histological injury,
and decreased kidney cortical TGF-b1 expression. ACE2 may
represent a therapeutic target in the prevention and
treatment of diabetic nephropathy.
MATERIALS AND METHODS
TG mice
The cDNA encoding the open reading frame of the human ACE2
gene, which contained a double hemagglutinin epitope tag at the 50
end, was inserted immediately downstream of the murine nephrin
promoter (provided by Dr C Kennedy, University of Ottawa,
Ottawa, ON, Canada), and cloned into the XhoI restriction site of
the expression vector pcDNA3 (Invitrogen, Carlsbad, CA). The
correct orientation of the insert was confirmed by DNA sequencing
(StemCore Laboratories, Ottawa Hospital Research Institute,
Ottawa, ON, Canada). Transfection of the expression plasmid
containing the cytomegalovirus promoter but lacking the nephrin
promoter into cultured COS-7 cells induced robust expression of
the human ACE2 protein, as determined by western blot analysis
(not shown). The linearized expression plasmid containing the
nephrin promoter was microinjected into FVB mouse embryos
(Charles River Laboratories, Wilmington, MA) and founder mice
were identified by DNA genotyping. Three mouse founder lines
were characterized for podocyte ACE2 expression, and one line was
selected for further studies.
Diabetes model
All mice used in these studies were on a congenic FVB/n background.
At 8 weeks of age, male WT and TG mice were injected over 5
consecutive days with either STZ (50mg/g per day intraperitoneally;
Sigma-Aldrich, St Louis, MO) or sodium-citrate vehicle. Hindlimb
blood glucose levels were monitored weekly by glucometer readings.
Urine was analyzed for ketones using Ketostix (Bayer HealthCare
LLC, Elkhart, IN). All mice were housed and cared for in the Animal
Care Facility at the University of Ottawa with free access to food and
water. All protocols were approved by the University of Ottawa
Animal Care Committee and conducted according to the guidelines
of the Canadian Council on Animal Care.
Systolic BP
Systolic BP was measured using tail-cuff plethysmography (BP-2000;
Visitech Systems, Apex, NC). Mice were trained at 6 weeks of age for
5 consecutive days and a baseline measurement was taken at 7 weeks
of age. Systolic BP was measured weekly from 1 week after STZ or
vehicle injection until 16 weeks.
Plasma analysis
At 16 weeks after injections, mice were anesthetized using isoflurane
and killed by cardiac puncture. Blood was collected with a
heparinized needle and plasma was separated by centrifugation at
3000 g for 10 min at 4 1C. Plasma electrolytes, glucose, albumin,
carbon dioxide, triglycerides, and cholesterol were assayed using the
Synchron CX5 Delta analyzer (Beckman Coulter, Fullerton, CA).
Glomerular isolation
Mice were anesthetized and cardiac perfusion was initiated with
4 107 Dynabeads (Invitrogen Dynal AS, Oslo, Norway), diluted in
20 ml of phosphate-buffered saline. Kidney cortices were digested in
collagenase Type 1 (1.0 mg/ml; Worthington Biochemical, Lakewood,
NJ) and DNase 1 (0.1 mg/ml; Roche Diagnostics, Indianapolis, IN) at
37 1C for 30 min, and tissue was passed through a 100mm sieve.
Glomeruli were isolated using a magnetic particle concentrator.36
Reverse transcriptase–PCR for human and mouse ACE2
RNA was isolated from glomeruli and other tissues for real-time
PCR for ACE2. Details of the protocol can be found in
Supplementary Information online.
Immunoblotting
Kidney cortical tissue and glomeruli were prepared for immunoblot
analysis with antibodies to ACE2, nephrin, and TGF-b1. Details of
the protocol can be found in Supplementary Information online.
Measurement of glomerular filtration rate
The glomerular filtration rate was measured in mice at 16 weeks of
study, using plasma fluorescein isothiocyanate–inulin clearance
kinetics, as we have described.37
Urinary albumin excretion
At 4, 8, and 16 weeks after injections, urine was collected over 24 h
in metabolic cages. Urinary albumin excretion was measured using a
murine albumin ELISA (Bethyl Laboratories, Montgomery, TX).
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Kidney histology
Dissected kidneys were incubated with 4% paraformaldehyde for
48 h at 4 1C, and were subsequently dehydrated, paraffin-embedded,
and cut into 4 mm sections. Sections were stained with periodic
acid–Schiff for measurement of mesangial and glomerular cross-
sectional areas. Podocyte counts were determined by staining for
WT-1,38 and immunofluorescent staining was performed for ACE2,
hemagglutinin, nephrin, and synaptopodin using standard proce-
dures. All analyses were performed in a blinded fashion. Details on
the histological protocols can be found in Supplementary Informa-
tion online.
ACE2 enzymatic activity assay
ACE2 activity in glomeruli and plasma was determined using a fluo-
rogenic ACE2 synthetic substrate, essentially as described.37,39 Details
of the assay can be found in Supplementary Information online.
Statistics
Data are presented as mean±s.e. Data were analyzed using
GraphPad Prism (Software version 4.02, San Diego, CA). For
multiple comparisons, analysis was by one-way analysis of variance
followed by Bonferroni or Newman–Keuls post-comparison test.
For comparisons involving two groups, Student’s t-test was used.
A P-value of o0.05 was considered statistically significant.
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